These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 14628977)

  • 1. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder.
    Hewlett WA; Schmid SP; Salomon RM
    J Clin Psychiatry; 2003 Sep; 64(9):1025-30. PubMed ID: 14628977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):375-80. PubMed ID: 24406025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.
    Connor KM; Payne VM; Gadde KM; Zhang W; Davidson JR
    J Clin Psychiatry; 2005 Jan; 66(1):49-51. PubMed ID: 15669888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients.
    Glick ID; Poyurovsky M; Ivanova O; Koran LM
    J Clin Psychiatry; 2008 Dec; 69(12):1856-9. PubMed ID: 19026264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
    Heidari M; Zarei M; Hosseini SM; Taghvaei R; Maleki H; Tabrizi M; Fallah J; Akhondzadeh S
    Int Clin Psychopharmacol; 2014 Nov; 29(6):344-50. PubMed ID: 24850229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder.
    Soltani F; Sayyah M; Feizy F; Malayeri A; Siahpoosh A; Motlagh I
    Hum Psychopharmacol; 2010 Aug; 25(6):509-13. PubMed ID: 20737524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ondansetron treatment in patients with Tourette's syndrome.
    Toren P; Laor N; Cohen DJ; Wolmer L; Weizman A
    Int Clin Psychopharmacol; 1999 Nov; 14(6):373-6. PubMed ID: 10565805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study.
    Sharafkhah M; Aghakarim Alamdar M; Massoudifar A; Abdolrazaghnejad A; Ebrahimi-Monfared M; Saber R; Mohammadbeigi A
    Int Clin Psychopharmacol; 2019 Sep; 34(5):222-233. PubMed ID: 31058716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
    Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
    J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature.
    Serata D; Kotzalidis GD; Rapinesi C; Janiri D; Di Pietro S; Callovini G; Piacentino D; Gasperoni C; Brugnoli R; Ferri VR; Girardi N; Tatarelli R; Ferracuti S; Angeletti G; Girardi P; Del Casale A
    Hum Psychopharmacol; 2015 Mar; 30(2):70-84. PubMed ID: 25676060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
    Broocks A; Pigott TA; Hill JL; Canter S; Grady TA; L'Heureux F; Murphy DL
    Psychiatry Res; 1998 Jun; 79(1):11-20. PubMed ID: 9676822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study.
    Vulink NC; Denys D; Westenberg HG
    J Clin Psychiatry; 2005 Feb; 66(2):228-30. PubMed ID: 15705009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower levels of whole blood serotonin in obsessive-compulsive disorder and in schizophrenia with obsessive-compulsive symptoms.
    Ma N; Tan LW; Wang Q; Li ZX; Li LJ
    Psychiatry Res; 2007 Feb; 150(1):61-9. PubMed ID: 17291595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.
    Sarris J; Oliver G; Camfield DA; Dean OM; Dowling N; Smith DJ; Murphy J; Menon R; Berk M; Blair-West S; Ng CH
    CNS Drugs; 2015 Sep; 29(9):801-9. PubMed ID: 26374743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
    Bogetto F; Bellino S; Vaschetto P; Ziero S
    Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
    Moreno FA; Wiegand CB; Taitano EK; Delgado PL
    J Clin Psychiatry; 2006 Nov; 67(11):1735-40. PubMed ID: 17196053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone as monotherapy for a patient with obsessive compulsive disorder comorbid with schizoaffective disorder: a case report.
    Chiou YJ; Lin PY; Lee Y
    Clin Neuropharmacol; 2015; 38(3):114-6. PubMed ID: 25970281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotine treatment of obsessive-compulsive disorder.
    Lundberg S; Carlsson A; Norfeldt P; Carlsson ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Nov; 28(7):1195-9. PubMed ID: 15610934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.